Technology
Health
Biotechnology

Novavax

$4.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-0.65%) Today
-$0.11 (-2.39%) As of 7:31 PM EDT after-hours

Why Robinhood?

You can buy or sell Novavax and other stocks, options, ETFs, and crypto commission-free!

About NVAX

Novavax, Inc. Common Stock, also called Novavax, is a late-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. Read More It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. Its vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Employees
379
Headquarters
Gaithersburg, Maryland
Founded
1987
Market Cap
108.21M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
538.75K
High Today
$4.70
Low Today
$4.50
Open Price
$4.70
Volume
411.42K
52 Week High
$51.60
52 Week Low
$4.38

Collections

Technology
Health
Biotechnology
US
North America

NVAX News

BenzingaJun 27

Novavax Takes Accelerated Approval Pathway For Flu Vaccine Development

7,051

NVAX Earnings

-$0.16
-$0.14
-$0.13
-$0.11
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 1, After Hours

Popular Stocks

More NVAX News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.